Migraine Disorders Archives - Medical Conferences

Migraine may be an important obstetric risk factor

Presented By

Dr Alexandra Purdue-Smithe, Harvard Medical School, MA, USA

Conference

AAN 2022

2 June, 2022 14:57

Intranasal zavegepant safe and well tolerated in healthy adults

Presented By

Prof. Richard Bertz, University of Pittsburgh, PA, USA

Conference

AAN 2022

2 June, 2022 14:52

Improvement of migraine using CGRP mAbs in a real-world setting

Presented By

Prof. Robert E. Shapiro, University of Vermont, VT, USA

Trial

OVERCOME

Conference

MTIS 2020

27 October, 2020 15:47

Similar treatment needs for high-frequency episodic and low-frequency chronic migraine

Presented By

Prof. Richard B. Lipton, Albert Einstein College of Medicine, NY, USA

Trial

CaMEO

Conference

MTIS 2020

27 October, 2020 15:44

Remote electrical neuromodulation useful for adolescents with migraine

Presented By

Dr Andrew D. Hershey, Cincinnati Children's Hospital Medical Center, USA

Conference

MTIS 2020

27 October, 2020 15:38

Concomitant preventive medication has no impact on efficacy of ubrogepant

Presented By

Dr Andrew M. Blumenfeld, Headache Center of Southern California, USA

Trial

Phase 3, ACHIEVE I and II

Conference

MTIS 2020

27 October, 2020 15:36

No new cardiovascular safety concerns with long-term use of lasmiditan

Presented By

Dr H. Hochstetler

Trial

Phase 3, GLADIATOR

Conference

MTIS 2020

27 October, 2020 15:19

Less medication use and fewer doctor visits with galcanezumab in treatment-resistant migraine

Presented By

Prof. Julio P. Gómez, Hospital Universitario Marqués de Valdecilla, Spain

Trial

Phase 3, CONQUER

Conference

MTIS 2020

27 October, 2020 15:16

Real-world evidence reveals physicians’ perception of erenumab

Presented By

Dr Mirja Koch, Clinical Research Neuroscience, Novartis Pharma GmbH, Germany

Trial

TELESCOPE

Conference

MTIS 2020

27 October, 2020 15:14

Early initiation of lasmiditan improves migraine outcomes

Presented By

Dr Mario F. Peres, Hospital Israelita Albert Einstein, Brazil

Trial

Phase 3, GLADIATOR

Conference

MTIS 2020

27 October, 2020 15:11

Fremanezumab effective in patients with migraine and comorbid depression

Presented By

Prof. Dawn C. Buse, Albert Einstein College of Medicine, NY, USA

Trial

Phase 3, FOCUS, HALO

Conference

MTIS 2020

27 October, 2020 15:08

Long-term onabotulinumtoxinA improves quality of life in migraine

Presented By

Dr Guy Boudreau, Centre Hospitalier Universitaire de Montréal, Canada

Trial

PREDICT

Conference

MTIS 2020

27 October, 2020 15:04

Sustained shift in migraine status using galcanezumab

Presented By

Dr William S. Kingston, Sunnybrook Health Sciences Centre, Canada

Trial

Phase 3, CONQUER

Conference

MTIS 2020

27 October, 2020 14:35

Worldwide survey shows substantial burden of migraine

Presented By

Dr D.D. Mitsikostas

Conference

MTIS 2020

27 October, 2020 14:33

Long-term efficacy and safety of fremanezumab in treatment-resistant migraine

Presented By

Dr M. Ashina

Trial

Phase 3, FOCUS

Conference

MTIS 2020

27 October, 2020 14:31

Injection-site reactions with galcanezumab are mild and self-limiting

Presented By

Dr V.L. Stauffer

Trial

Phase 3, CONQUER

Conference

MTIS 2020

27 October, 2020 14:27

Migraine as a cyclical functional disorder

Presented By

Mr Daniele Martinelli, University of Pavia, Italy

Conference

EAN 2020

10 September, 2020 11:07

Reassuring real-world safety profile of 3 CGRP inhibitors

Presented By

Prof. Stephen D. Silberstein, Thomas Jefferson University, PA, USA

Conference

EAN 2020

10 September, 2020 11:03

Long-term cardiovascular safety of erenumab

Presented By

Dr Stewart Tepper, Geisel School of Medicine, USA

Conference

EAN 2020

10 September, 2020 10:58

Real-world data for erenumab in Germany

Presented By

Prof. Andreas Straube, Ludwig-Maximilians-University Munich, Germany

Trial

TELESCOPE

Conference

EAN 2020

9 September, 2020 17:13

Eptinezumab in chronic migraine and medication-overuse headache

Presented By

Prof. Hans-Christoph Diener, Medical Faculty of the University Duisburg-Essen, Germany

Trial

Phase 3, PROMISE-2

Conference

EAN 2020

9 September, 2020 17:09

Fremanezumab tolerability in cardiovascular patients with migraine

Presented By

Dr Gianluca Coppola, Sapienza University of Rome, Italy

Trial

Phase 3, HALO, FOCUS

Conference

EAN 2020

9 September, 2020 17:05

Effects of galcanezumab on health-related quality of life

Presented By

Dr Stewart Tepper, Geisel School of Medicine, USA

Trial

Phase 3, CONQUER

Conference

EAN 2020

9 September, 2020 16:44

Unmet needs and pipeline

Presented By

Prof. Christian Lampl, Headache Medical Center, Austria

Conference

EAN 2020

9 September, 2020 16:39